Key Insights

Highlights

Success Rate

97% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

1.7%

1 terminated out of 58 trials

Success Rate

96.7%

+10.1% vs benchmark

Late-Stage Pipeline

17%

10 trials in Phase 3/4

Results Transparency

10%

3 of 29 completed with results

Key Signals

3 with results97% success

Data Visualizations

Phase Distribution

50Total
Not Applicable (28)
P 1 (7)
P 2 (5)
P 3 (3)
P 4 (7)

Trial Status

Completed29
Unknown12
Recruiting6
Active Not Recruiting4
Not Yet Recruiting3
Withdrawn2

Trial Success Rate

96.7%

Benchmark: 86.6%

Based on 29 completed trials

Clinical Trials (58)

Showing 20 of 20 trials
NCT05828823Not ApplicableRecruitingPrimary

Incremental Hemodialysis: The TwoPlus Trial

NCT06877169Not ApplicableRecruiting

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

NCT07678710Completed

Assessment of Left Ventricular Myocardial Dysfunction in Children With End-Stage Kidney Disease Using Two-Dimensional and Three-Dimensional Speckle-Tracking Echocardiography

NCT07618858Not ApplicableNot Yet RecruitingPrimary

Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration

NCT04646226Not ApplicableActive Not RecruitingPrimary

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04877041Not ApplicableCompletedPrimary

Exercise and Cardiac Stunning During HD

NCT05449067Not ApplicableCompletedPrimary

Nocturnal APD vs. CAPD in Non-diabetic ESKD

NCT04079582Not ApplicableActive Not Recruiting

Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag)

NCT05879302Not ApplicableCompleted

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

NCT05027074Phase 2Completed

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

NCT05931276Phase 3RecruitingPrimary

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

NCT06814132Phase 1Completed

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

NCT06693765Phase 1Completed

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

NCT05656040Phase 1Completed

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

NCT05614115Phase 1CompletedPrimary

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

NCT06377293Not ApplicableActive Not RecruitingPrimary

Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients

NCT05515991Not ApplicableActive Not RecruitingPrimary

Symptom Management in Patients on Dialysis

NCT06842927Enrolling By InvitationPrimary

Dialysis Efficiency and Transporter Evaluation Computational Tool in Peritoneal Dialysis

NCT02823821Phase 4RecruitingPrimary

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

NCT02832505Withdrawn

Applications of MRI in Kidney Disease

Scroll to load more

Research Network

Activity Timeline